Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... 2014 In November 2012, the European Union ... Report (PBRER) in a new PSUR – responding to the ... profile of a drug. Adopted in many regions, the main ... Present a comprehensive and critical analysis of new or emerging ... Highlight any new evidence of the potential benefits of a ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industry” is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4
... Jan. 26, 2011 LABS Inc., the premier transplant ... that Kimberly Elliott has joined the Company as Sales ... in the donor and tissue services industry. At LABS ... existing clientele, entering new markets and building national sales ...
... Kyoto, Japan -- Certain types of pollution monitoring may ... at Kyoto University has shown in a recent ... of porous crystals (porous coordination polymers, or PCPs) can ... but that the mixtures then glow in specific, easily-detected ...
... Jan. 25, 2011 Thomas, McNerney & Partners, LLC, ... life science and medical technology companies, today announced the ... to Vice President. "These promotions are much-deserved ... made as members of the Thomas, McNerney investment team," ...
Cached Biology Technology:Kimberly (Lewis) Elliott Joins LABS Inc. as Sales Manager 2Thomas, McNerney & Partners Promotes Two Members of its Investment Team 2
(Date:8/19/2014)... LAWRENCE It,s not a monkey. It,s not a lemur. ... Mouse. Meet the Philippine tarsier: a tiny, adorable and downright ... any animals that Americans are familiar with," said Rafe Brown, ... has giant eyes and ears; an extremely cute, furry body; ... and interesting expanded fingers and toe tips that look a ...
(Date:8/19/2014)... from fish purchased at retail seafood counters in ... mislabeling can expose consumers to unexpectedly high levels ... "substitutions"which falsely present a fish of the same ... most dangerous mislabeling offense, according to new research ... "Accurate labeling of seafood is essential to allow ...
(Date:8/19/2014)... scientists have identified a biomarker strongly associated with ... is resistant to many types of chemotherapy. The ... target for new therapeutics designed to treat this ... data taken from The Cancer Genome Atlas, molecular ... used powerful computational and bioinformatics techniques to detect ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... sea levels, melting glaciers, more intense rainstorms and more ... may come to mind when climate change is mentioned. ... risk of avian influenza transmission in wild birds can ... Rohani and Victoria Brown used a mathematical model to ...
... of Hawaii Manoa (UHM) School of Ocean and Earth ... major theory in the field of coral reef ecology. ... are, regarding which species of single celled algae ( Symbiodinium ... will have to survive environmental stress. In their paper published ...
... the cycles of day and night, and most organisms carry in ... emerges from a tiny brain structure called the suprachiasmatic nucleus (SCN) ... it alive in a lab dish and this "brain clock" will ... proteins at specific times of the day, day after day. ...
Cached Biology News:Climate change could increase levels of avian influenza in wild birds 2Climate change could increase levels of avian influenza in wild birds 3Less is more for reef-building corals 2Less is more for reef-building corals 3Metabolism in the brain fluctuates with circadian rhythm 2